The Senate Human Services Committee convened on February 10, 2025, to discuss critical issues surrounding insulin affordability and access in North Dakota. The meeting featured testimonies from advocates and concerned citizens, highlighting the ongoing struggles faced by individuals with diabetes due to rising insulin costs.

The session began with a presentation by Miss Frick, who reported on recent reductions in insulin prices by major pharmaceutical companies. She noted that these changes resulted in an average savings of $80.15 per member per month, attributing this to significant shifts in the market. The committee then opened the floor for public testimony.

Danelle Johnson, a long-time advocate for insulin affordability, shared her personal experiences and the challenges her family has faced over the years. Johnson emphasized the urgency of the issue, citing that 26 states have enacted some form of insulin copay cap. She expressed concern over the potential consequences of inaction, stating that the lack of affordable insulin could lead to severe health complications and even death for those unable to manage their diabetes effectively.

Johnson also referenced a recent settlement in Minnesota, which allows residents to purchase insulin at a capped price of $35 per vial, contrasting it with North Dakota's current situation. She urged the committee to consider the broader implications of their decisions, noting that the financial burden of insulin can lead families to forgo other essential expenses.

Angela Kurtzberger, another advocate and mother of a type 1 diabetic, echoed Johnson's sentiments. She described the daily challenges her daughter faces in managing her condition and the financial strain of high insurance premiums and deductibles. Kurtzberger highlighted the need for legislative action to ensure that young adults transitioning out of their parents' insurance plans can still access affordable insulin.

Throughout the meeting, committee members engaged with the testimonies, asking questions and seeking clarification on the proposed solutions. The discussions underscored the critical need for comprehensive policies that address the affordability of insulin and the broader healthcare landscape in North Dakota.

As the meeting concluded, the committee acknowledged the importance of the testimonies presented and the pressing need for legislative action to support individuals living with diabetes. The next steps will involve further deliberation on proposed bills aimed at capping insulin costs and improving access to essential medications for all North Dakotans.